Scroll To Top
News

Med Monitor

Med Monitor

55_cover_2

The Food and Drug Administration approved the first single-capsule, once-a-day protease inhibitor in late October. Reyataz is now available in 300-milligram form, to be boosted with Norvir. ----- The French National Agency for Research on AIDS has released study results that show the risk of mother-to-child HIV transmission can be greatly reduced by combining treatment of AZT and lamivudine at the end of pregnancy and during delivery with alternatives to breast feeding. ----- Boehringer-Ingelheim has halted a three-year study of protease inhibitor Aptivus among treatment-naive HIVers because of poor viral control. The proportion of study subjects who achieved a viral load below 50 after 48 weeks of treatment with 500 milligrams of Aptivus plus a booster dose of Norvir was more than 15% lower than those taking Kaletra. ----- Protease inhibitors Lexiva and Kaletra are similar in safety and effectiveness, according to a 48-week, 878-patient study published in the August 5 edition of The Lancet, leading researchers to conclude that Lexiva could soon be considered a preferred protease option on par with Kaletra. ----- A three-year study of 765 patients reported in The Journal of the American Medical Association has found no advantage in adding a fourth drug to the standard three-drug cocktail for treating newly diagnosed HIV patients. Researchers gave two groups of treatment-naive patients each a regimen containing five pills daily. The researchers found the four-drug cocktail, which added abacavir, offered no benefit over the three-drug cocktail either in terms of reduced viral load or increased CD4-cell count.

Out Subscription Lil Nas XAdvocateChannel promotion

From our Sponsors

Most Popular

Fifth Person Cured of HIV

Be sure to follow Plus on your favorite social platforms!

FacebookInstagramTwitter

Want more news, top stories, and videos? Check out the all NEW Advocate Channel!
Your 24/7 streaming source for equality news and lifestyle trends.
Click this link right now:
https://advocatechannel.com

Latest Stories